Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | May 30, 2024 | June 03, 2024 |
| Immunovant, Inc.IMVT · Entity 3632 | Director · Chief Executive Officer | April 16, 2025 | April 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 2,783 |
Reported balance
After 2024-05-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 2,783 · Balance 2,783 F1: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
Immunovant, Inc.
Report date April 16, 2025 · Filed April 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,178,191 |
Reported balance
After 2025-04-16 transaction · row 1
1 source rowRow 1 · 2025-04-16 · Sale · Disposed 8,321 · Balance 1,178,191 F1: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,240 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,240 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2025 Filed Apr 17, 2025 20:07 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 8,321 | $14.89 | $123,899.69 |
DisclosureSEC source: 0001764013-25-000075 · wk-form4_1744920441.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,178,191 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,240 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 20:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 28,094 | $12.99 | $364,941.06 |
DisclosureSEC source: 0001764013-25-000066 · wk-form4_1744401896.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,186,512 F1 · shares: On April 2, 2024, the holder was granted 160,534 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 40,133 of these RSUs vested on April 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 - $13.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 374,395 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000049 · wk-form4_1743713207.xml · derivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,395 Underlying: Common Stock · 374,395 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 265,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000049 · wk-form4_1743713207.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,214,606 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:04 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 15,439 | $20.86 | $322,057.54 |
DisclosureSEC source: 0001764013-25-000030 · wk-form4_1740171852.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 948,786 F1 · shares: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:04 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 415 | $24.19 | $10,038.85 |
DisclosureSEC source: 0001764013-25-000013 · wk-form4_1737147867.xml · nonDerivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,225 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,239 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:04 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 8,352 | $23.81 | $198,861.12 |
DisclosureSEC source: 0001764013-25-000013 · wk-form4_1737147867.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,640 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,239 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 5,105 | $24.10 | $123,030.50 |
DisclosureSEC source: 0001764013-25-000003 · wk-form4_1736543457.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 972,992 F1 · shares: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,282 of these RSUs vested on January 1, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.91 - $24.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:08 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 16,692 | $25.45 | $424,811.40 |
DisclosureSEC source: 0001764013-24-000193 · wk-form4_1732309693.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 978,097 F1 · shares: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:31 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 9,095 | $28.79 | $261,845.05 |
DisclosureSEC source: 0001764013-24-000174 · wk-form4_1729283466.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994,789 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,240 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:02 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,460 | $29.56 | $131,837.60 |
DisclosureSEC source: 0001764013-24-000165 · wk-form4_1728676955.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,003,884 F1 · shares: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on October 1, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.28 - $29.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:07 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 598 | $32.32 | $19,327.36 |
DisclosureSEC source: 0001764013-24-000156 · wk-form4_1724443632.xml · nonDerivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,008,344 F1 · shares: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 - $32.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:07 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 14,470 | $31.84 | $460,724.80 |
DisclosureSEC source: 0001764013-24-000156 · wk-form4_1724443632.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,008,942 F1 · shares: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 - $32.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:36 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 510 | $30.55 | $15,580.50 |
DisclosureSEC source: 0001764013-24-000133 · wk-form4_1721424975.xml · nonDerivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,023,412 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,239 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 - $30.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:36 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 8,175 | $29.64 | $242,307.00 |
DisclosureSEC source: 0001764013-24-000133 · wk-form4_1721424975.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,023,922 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,239 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 - $30.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 21:04 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,619 | $28.06 | $129,609.14 |
DisclosureSEC source: 0001764013-24-000125 · wk-form4_1720645470.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,032,097 F1 · shares: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on July 1, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.48 - $28.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:30 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068030 · ownership.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F1 · balance_after: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 16,163 | $29.65 | $479,232.95 |
DisclosureSEC source: 0001764013-24-000098 · wk-form4_1716581737.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,036,716 F1 · shares: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on May 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 - $30.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 16, 2024 Filed May 20, 2024 21:00 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 2,783 | $0.00 Strike: $45.92 | $0.00 |
DisclosureSEC source: 0001209191-24-005676 · doc4.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 Underlying: Common Stock · 2,783 shares Expires 2034-05-16 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 21:57 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 7,714 | $29.94 | $230,957.16 |
DisclosureSEC source: 0001764013-24-000075 · wk-form4_1713563823.xml · nonDerivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,052,879 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 60,958 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 - $30.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 21:57 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 26,365 | $28.80 | $759,312.00 |
DisclosureSEC source: 0001764013-24-000075 · wk-form4_1713563823.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,060,593 F1 · shares: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 60,958 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 - $29.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 20:14 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,807 | $31.18 | $149,882.26 |
DisclosureSEC source: 0001764013-24-000069 · wk-form4_1712780038.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,086,958 F1 · shares: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on April 1, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.73 - $31.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:23 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 200,667 | $0.00 Strike: $30.78 | $0.00 |
DisclosureSEC source: 0001764013-24-000044 · wk-form4_1712262227.xml · derivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,667 Underlying: Common Stock · 200,667 shares Expires 2034-04-02 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:23 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 160,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000044 · wk-form4_1712262227.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,091,765 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 13,454 | $36.15 | $486,362.10 |
DisclosureSEC source: 0001764013-24-000037 · wk-form4_1708722641.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 931,231 F1 · security: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on February 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.85 - $36.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:18 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,824 | $38.59 | $147,568.16 |
DisclosureSEC source: 0001764013-24-000006 · wk-form4_1704835104.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944,685 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,282 of these RSUs vested on January 1, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.59 - $39.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 19:55 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 616 | $33.52 | $20,648.32 |
DisclosureSEC source: 0001764013-23-000146 · wk-form4_1700855717.xml · nonDerivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 948,509 F1 · security: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.46 - $33.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 19:55 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 15,601 | $32.75 | $510,932.75 |
DisclosureSEC source: 0001764013-23-000146 · wk-form4_1700855717.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 949,125 F1 · security: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 - $33.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 21:10 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,345 | $36.39 | $158,114.55 |
DisclosureSEC source: 0001764013-23-000117 · wk-form4_1696626599.xml · nonDerivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,726 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on October 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.92 - $36.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4 Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 21:10 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 894 | $35.54 | $31,772.76 |
DisclosureSEC source: 0001764013-23-000117 · wk-form4_1696626599.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 969,071 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on October 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.90 - $35.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:08 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 5,908 | $22.48 | $132,811.84 |
DisclosureSEC source: 0001764013-23-000107 · wf-form4_169359887938473.xml · nonDerivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 969,965 F1 · security: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 112,816 of these RSUs vested on August 17, 2023. Settlement with respect to the 112,816 vested RSUs was deferred and amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.43 - $22.59 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:08 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 50,866 | $21.97 | $1,117,526.02 |
DisclosureSEC source: 0001764013-23-000107 · wf-form4_169359887938473.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 975,873 F1 · security: On August 17, 2022, the holder was granted 451,264 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 112,816 of these RSUs vested on August 17, 2023. Settlement with respect to the 112,816 vested RSUs was deferred and amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.43 - $22.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 20:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 11,314 | $22.04 | $249,360.56 |
DisclosureSEC source: 0001764013-23-000094 · wf-form4_169221665635652.xml · nonDerivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,026,739 F1 · security: On August 3, 2021, the holder was granted 570,613 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 356,633 of these RSUs vested on August 3, 2023. As previously reported on a Form 4 filed on August 8, 2023, settlement was deferred with respect to 178,317 of the vested RSUs. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the remaining settlement of 178,317 of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.88 - $22.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 20:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 91,744 | $21.34 | $1,957,816.96 |
DisclosureSEC source: 0001764013-23-000094 · wf-form4_169221665635652.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,038,053 F1 · security: On August 3, 2021, the holder was granted 570,613 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 356,633 of these RSUs vested on August 3, 2023. As previously reported on a Form 4 filed on August 8, 2023, settlement was deferred with respect to 178,317 of the vested RSUs. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the remaining settlement of 178,317 of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.88 - $21.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 20:44 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 101,339 | $21.73 | $2,202,096.47 |
DisclosureSEC source: 0001764013-23-000087 · wf-form4_169152738079375.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,129,797 F1 · security: On August 3, 2021, the holder was granted 570,613 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 356,633 of these RSUs vested on August 3, 2023. Settlement was deferred with respect to 178,317 of the vested RSUs. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of 178,316 of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.26 - $22.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 12, 2023 Filed Jul 13, 2023 21:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,233 | $19.73 | $63,787.09 |
DisclosureSEC source: 0001764013-23-000078 · wf-form4_168928269599746.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,231,136 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on July 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.39 - $20.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:24 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001209191-23-031460 · doc4.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2033-05-18 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest 100% on the one year anniversay from the date of grant. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 20:09 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,395 | $15.27 | $51,841.65 |
DisclosureSEC source: 0001764013-23-000049 · wf-form4_168193494493140.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,234,369 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on April 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.08 - $15.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:14 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 316,585 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001764013-23-000038 · wf-form4_168150324964962.xml · derivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,585 Underlying: Common Stock · 316,585 shares Expires 2033-04-12 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 12, 2024 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:14 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 243,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-23-000038 · wf-form4_168150324964962.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,237,764 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on April 12, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 13:21 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,021 | $16.80 | $67,552.80 |
DisclosureSEC source: 0001764013-23-000012 · wf-form4_167361610100577.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 993,932 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,282 of these RSUs vested on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.76 - $16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 12:57 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,793 | $9.18 | $25,639.74 |
DisclosureSEC source: 0001764013-22-000130 · wf-form4_166601145413186.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 997,953 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 8,281 of these RSUs vested on October 1, 2022 and the remainder of the RSUs vest in quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.18 - $9.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 28, 2022 Filed Sep 29, 2022 21:06 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,605 | $4.67 | $7,495.35 |
DisclosureSEC source: 0001764013-22-000122 · wf-form4_166448557706339.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,746 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 2,760 of these RSUs vested on September 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 11:36 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,644 | $5.83 | $9,584.52 |
DisclosureSEC source: 0001764013-22-000112 · wf-form4_166203216200949.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,002,351 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 2,761 of these RSUs vested on August 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:50 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 678,592 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001764013-22-000099 · wf-form4_166094221021747.xml · derivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,592 Underlying: Common Stock · 678,592 shares Expires 2032-08-17 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on August 17, 2023 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:50 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 451,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000099 · wf-form4_166094221021747.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,003,995 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on August 17, 2023 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 11:36 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,528 | $4.27 | $6,524.56 |
DisclosureSEC source: 0001764013-22-000077 · wf-form4_165909456363894.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,731 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 2,760 of these RSUs vested on July 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 11:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,376 | $4.02 | $5,531.52 |
DisclosureSEC source: 0001764013-22-000072 · wf-form4_165667352814683.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,259 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 2,761 of these RSUs vested on June 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.02 - $4.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:23 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,471 | $3.79 | $5,575.09 |
DisclosureSEC source: 0001764013-22-000045 · wf-form4_165351019453934.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,635 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 2,760 of these RSUs vested on May 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.79 - $3.82 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 18, 2022 Filed May 19, 2022 18:34 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 79,600 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-22-030444 · doc4.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,600 Underlying: Common Stock · 79,600 shares Expires 2032-05-18 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.